MULTIPLE MYELOMA
and related malignancies

5th Edition 2020

Presidents
Prof. Angelo Vacca
Prof. Pellegrino Musto
Prof. Roberto Ria

November 5-7, 2020
Under the auspices of:

SIE
Società Italiana di Ematologia

SIEg
Società Italiana di Ematologia Sperimentale

SIMI
Società Italiana di Medicina Interna
Patrocinio
In the last 10 years significant advancements in the understanding of the pathophysiology of multiple myeloma and related malignancies have led to the adoption of new effective and safe therapies. Thus, the time has come for a thorough biological and clinical update. In planning this international meeting, we have indeed kept in mind this aim which will hopefully provide specialists in Hematology, Oncology, Immunology, Internal Medicine, Infectious diseases, Orthopedy, Radiology and Radiotherapy, as well as Biologists and Biotechnologists, and young researchers, residents, doctoral and undergraduate students with a great opportunity to deepen and update their knowledge on the available and emerging developments in the biology and management of multiple myeloma and related malignancies.

A number of internationally recognized speakers, are expected to deliver state-of-the-art lectures on cutting edge topics. These will include genetic and epigenetic features of myeloma biology, molecular and biological mechanisms of disease progression, new prognostic factors and novel approaches for evaluate the response to therapy, new therapeutic molecules and combinations thereof specifically targeting tumor cells and/or their microenvironment. Autologous and allogeneic stem cell transplantation will also be the object of intensive scrutiny. Based on these premises, we are confident that at the end of the meeting all of us will be enriched with fresh stimuli and renewed enthusiasm, with the deep awareness that the enduring challenges posed by multiple myeloma and cognate tumors may now be faced with more rational and more effective achievements.

Angelo Vacca, Pellegrino Musto, Roberto Ria
09.20-09.30  Welcome speech and orientation  
*Angelo Vacca, Pellegrino Musto, Roberto Ria*

09.30-12.40  **Workshop 1**  
**Biology, Bone Disease and Immunodeficiency of Myeloma**  
Coordinator: *Angelo Vacca (Bari, IT)*

09.30-09.50  *Kim De Veirman (Brussels, BE)*  
Bone marrow microenvironment and MGUS progression

09.50-10.10  *Niccolò Bolli (Milan, IT)*  
Genomic profiling of monoclonal gammopathies: MGUS/SM and overt MM

10.10-10.30  *Cirino Botta (Cosenza, IT)*  
Single cell characterization of MM immune microenvironment

10.30-10.50  *Nicola Giuliani (Parma, IT)*  
Bone destruction in MM: can biology help the clinician?

10.50-11.10  *G. David Roodman (Indianapolis, USA)*  
Myeloma bone disease: Pathogenesis and Treatment

11.10-11.20  *Pause*

11.20-11.40  *Ivan Borrello (Baltimore, USA)*  
Marrow Infiltrating Lymphocytes: Insights into their biology and clinical use

11.40-12.00  *Angelo Vacca (Bari, IT)*  
Endothelial cells and fibroblasts as immunosuppressive agents in MM

12.00-12.20  *Massimo Massaia (Cuneo, IT)*  
Decoding the immune suppressive network with Vγ9Vδ2 T cells

12.20-12.40  *Roberto Ria (Bari, IT)*  
Prophylaxis of infections in patients with multiple myeloma in the era of the newest drugs
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>15.30-18.40</td>
<td><strong>Workshop 2</strong>&lt;br&gt;Diagnosis, Prognosis and Clinical Features&lt;br&gt;Coordinator: Gianpietro Semenzato (Padua, IT)</td>
</tr>
<tr>
<td>15.30-15.50</td>
<td><strong>Elena Zamagni</strong> (Bologna, IT)&lt;br&gt;Imaging techniques and applications in MM</td>
</tr>
<tr>
<td>15.50-16.10</td>
<td><strong>Andrew Spencer</strong> (Melbourne, AU)&lt;br&gt;DNA repair gene mutations in multiple myeloma</td>
</tr>
<tr>
<td>16.10-16.30</td>
<td><strong>Aldo M. Roccaro</strong> (Brescia, IT)&lt;br&gt;Transcriptome of malignant plasma cells</td>
</tr>
<tr>
<td>16.30-16.50</td>
<td><strong>Bruno Paiva</strong> (Pamplona, ES)&lt;br&gt;Circulating tumor cells for non-invasive genetic characterization of MM</td>
</tr>
<tr>
<td>16.50-17.10</td>
<td><strong>Hervé Avet-Loiseau</strong> (Toulouse, FR)&lt;br&gt;How to define high-risk myeloma</td>
</tr>
<tr>
<td>17.10-17.20</td>
<td><strong>Pause</strong></td>
</tr>
<tr>
<td>17.20-17.40</td>
<td><strong>Roger G. Owen</strong> (Leeds, UK)&lt;br&gt;Evaluation of MRD in MM</td>
</tr>
<tr>
<td>17.40-18.00</td>
<td><strong>Maria Victoria Mateos</strong> (Salamanca, ES)&lt;br&gt;Smoldering myeloma: new concepts in preventing progression</td>
</tr>
<tr>
<td>18.00-18.20</td>
<td><strong>Roman Hájek</strong> (Ostrava, CZ)&lt;br&gt;An importance of real world evidence in multiple myeloma</td>
</tr>
<tr>
<td>18.20-18.40</td>
<td><strong>Francesco Di Raimondo</strong> (Catania, IT)&lt;br&gt;Diagnostic criteria, response assessment, and workup at the end of 2020</td>
</tr>
</tbody>
</table>
09.30-12.40  Workshop 3
First Line Therapy
Coordinator: Alessando Corso (Legnano, IT)

09.30-10.00  Lecture
Faith E. Davies (New York - USA)
Is precision medicine a feasible approach to multiple myeloma?

10.00-10.20  Maria Teresa Petrucci (Rome, IT)
Upfront treatment in young patients: toward new induction regimens

10.20-10.40  Mohamad Mohty (Paris, FR)
Auto-SCT vs novel agents

10.40-11.00  Alessandro Corso (Legnano, IT)
Upfront treatment in young patients: what maintenance therapy and how long

11.00-11.10  Pause

11.10-11.30  Francesca Gay (Turin, IT)
Treatment of newly diagnosed myeloma in elderly patients

11.30-11.50  Alessandra Larocca (Turin, IT)
Multiple myeloma and aging

11.50-12.10  Francesca Patriarca (Udine, IT)
What are the approaches to achieve the best possible outcomes in myeloma?

12.10-12.40  Concluding lecture
Morie Gertz (Rochester, USA)
Continuous treatment: pro and contras
15.30-18.30 Workshop 4
Relapsed/Refractory Myeloma and the Newest Drugs
Coordinator: Roberto Ria (Bari, IT)

15.30-15.50 Anders Waage (Trondheim, NO)
Treatment options at first relapse

15.50-16.10 Inger S. Nijhof (Amsterdam, NL)
Refractory disease

16.10-16.30 Gordon Cook (Leeds, UK)
New therapeutic approaches for relapsed/refractory patients

16.30-16.50 Paola Neri (Calgary, CA)
Immunome single cell profiling to identify mechanisms of tumoral escape in Daratumumab-treated Myeloma patients

16.50-17.00 Pause

17.00-17.20 Paolo Corradini (Milan, IT)
Car T cells: a new hope?

17.20-17.40 Annie Reale (Melbourne, AU)
New targets and new approaches: latest advances in extracellular vesicles

17.40-18.00 Niels Van de Donk (Amsterdam, NL)
The evolving role of immunotherapy in MM patients

18.00-18.30 Concluding lecture
Herman Einsele (Würzburg, DE)
Bispecific antibodies and novel cellular therapies
09.30-12.20  **Workshop 5**  
**Plasma Cell Dyscrasias, Progression, and Management**  
Coordinator: **Pellegrino Musto (Bari, IT)**

09.30-09.50  **Carolina Terragna (Bologna, IT)**  
Role of clonal evolution in MM progression and refractoriness

09.50-10.10  **Pellegrino Musto (Bari, IT)**  
Management of primary plasma cell leukemia

10.10-10.30  **Franco Dammacco (Bari, IT)**  
What is new in the diagnosis and treatment of Waldenström’s macroglobulinemia

10.30-10.50  **Stefan Schönland (Heidelberg, DE)**  
New strategies for the treatment of AL amyloidosis

10.50-11.00  *Pause*

11.00-11.20  **Laura Rosiñol (Barcelona, ES)**  
Management of renal impairment in MM

11.20-11.40  **Daniele Derudas (Cagliari, IT)**  
Monoclonal gammopathies of renal significance

11.40-12.00  **Meral Beksac (Ankara, TR)**  
Extramedullary myeloma: an unmet need

12.00-12.20  Summing-up and Closing  
**Angelo Vacca, Roberto Ria, Pellegrino Musto**
REGISTRATION FEE
The registration fee is 100,00 EUR (+ VAT 22%)

PAYMENT
Payment of registration fee can be made through the website www.meeting-planner.it (select the congress in the section “Calendario eventi” - FAD).
Payments can be made by credit card or by bank transfer (all transaction fees should be paid by the participant).
An invoice will be sent as confirmation of the registration.

CANCELLATION POLICY
Cancellations must be notified in writing to the Conference Secretariat (stella@meeting-planner.it).
For cancellations received by October 15, 2020: 100% refund (less a EUR 20,00 of administrative charge).
No refund will be made for cancellations received after that date or for no-shows.
Please note that refunds will only be processed by bank transfer after the Conference dates.

CONTINUING MEDICAL EDUCATION (CME) - event n. 303981
This Congress has been assigned n. 21 credits.
This training event is for 200 attendees. Medical specialists in the following areas: Internal Medicine, Allergology and Clinical Immunology, Hematology, Oncology, Infectious diseases, Radiology, Radiotherapy, Orthopedics and traumatology and Clinical Biochemistry.
Other healthcare professionals: Biologists and Nurses.
CME credits can be claimed and your CME certificate issued only if you:
• have attended the entire training event
• have passed the CME assessment survey (a score of 75% or higher must be attained)
There can be no exceptions to these mandatory steps.
Attendants are also required not to exceed acquiring over 1/3 of their credits for the three-year period (2020-2022) by recruitment invitation.

AIMS OF THE TRAINING PROCESS:
Guidelines, Protocols, Procedures (2)

LANGUAGE
The official language is English.
Recommended devices: PC/LAPTOP/MAC
Browser: GOOGLE CHROME

PROVIDER AND ORGANIZING SECRETARIAT
MEETING PLANNER
Via Divisione Paracadutisti Folgore, 5 - 70125 BARI (Italy)
TEL. +39 080 9905360 • FAX +39 080 9905359 • +39 080 2140203
E-mail: info@meeting-planner.it - www.meeting-planner.it
With the unconditional sponsorship of: